Helix BioPharma Corp and Helix Immuno-Oncology to present at AACR in Chicago

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that together with its wholly-owned subsidiary Helix Immuno-Oncology, it will present a poster entitled: Targeting Urease to Human VEGFR2
Elicits Antitumor Activity in Triple-Negative Breast Cancer Models at the American Association for Cancer Research (“AACR”) Annual Meeting 2018 which is taking place on April 14 – 18, 2018 at McCormick Place in Chicago, Illinois.

The presentation will describe preclinical development of V-DOS47 for the potential treatment of certain forms of breast cancer. V-DOS47 is a second therapeutic candidate derived from the DOS47 platform.